Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing.
BACKGROUND
Prior to the discovery of the Huntington's disease (HD) mutation, the prevalence, incidence, and new mutation rates for this disease were based on the presence of progressive choreic movements and a positive family history.


OBJECTIVE
To evaluate the uptake of the HD genetic analysis in Spain, and to provide additional information on the epidemiology of this disease from the experience of 9 years of direct genetic testing.


METHODS
From 1994 to 2002, CAG repeat length was determined in 317 patients with symptoms compatible with HD. In all cases, demographic, clinical, and family data were carefully reviewed.


RESULTS
HD diagnosis (CAG repeat length >/=36) was confirmed in 166 (52%) symptomatic cases. Of these, 76 (45.8%) reported a positive family history and in 21 cases (12.7%) family history was negative. New mutation events were genetically proven in three families and highly suspected in another, estimating that the minimum new mutation rate for HD in our population is >4%, with a potential mutation rate of 8%. More than 16% of all HD cases had late onset (>59 years) of symptoms, and in three quarters of these the family history was negative. The incidence rate for the autonomous communities of Navarra and the Basque country, based on the number of newly diagnosed cases by genetic testing, was 4.7 per million per year.


CONCLUSIONS
Direct HD genetic testing shows that the incidence and mutation rates of the disease are 2-3 times higher than previously reported. We also demonstrated the relevance of CAG repeat length assessment in diagnosing patients with late onset of symptoms and negative family history for HD.
Ramos-Arroyo
M A
MA
Servicio de Genética Médica, Hospital Virgen del Camino, C/ Irunlarrea 4, 31008 Pamplona, Navarra, Spain. ma.ramos.arroyo@cfnavarra.es
Moreno
S
S
Valiente
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004252:DNA Mutational Analysis; D018450:Disease Progression; D016021:Epidemiologic Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006801:Humans; D006816:Huntington Disease / Q000453:epidemiology* / Q000235:genetics*; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D015995:Prevalence; D013030:Spain / Q000453:epidemiology; D018911:Trinucleotide Repeats
Am J Hum Genet. 2001 Feb;68(2):373-85
11225602
Rev Neurol. 1997 Dec;25(148):1845-7
9528016
Rev Clin Esp. 1970 Dec 30;119(4):333-44
4250824
Am J Hum Genet. 1984 May;36(3):506-26
6233902
Hum Genet. 1992 Jun;89(4):365-76
1535611
Mol Cell Probes. 1993 Jun;7(3):235-9
8366869
Nat Genet. 1993 Aug;4(4):398-403
8401589
Nat Genet. 1993 Oct;5(2):174-9
8252043
Am J Hum Genet. 1994 May;54(5):852-63
8178825
Arch Neurol. 1994 Jul;51(7):696-8
8018043
J Neurol Neurosurg Psychiatry. 1995 Apr;58(4):496-8
7738566
Eur Neurol. 1996;36(6):348-52
8954302
Med Clin (Barc). 1997 May 10;108(18):687-90
9324583
Age Ageing. 1994 Nov;23(6):445-8
9231935
J Med Genet. 2000 Aug;37(8):567-71
10922381
Hum Mol Genet. 1997 Nov;6(12):2005-10
9328463
Clin Genet. 2001 Sep;60(3):198-205
11595021